Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses TRDA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TRDA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dipal Doshi | $635,000 | $0 | $1,387,428 | $1,452,059 | $349,250 | $0 | $14,000 | $3,837,737 |
| Chief Executive Officer | ||||||||
| Natarajan Sethuraman | 520,000 | 0 | 725,952 | 760,363 | 234,000 | 0 | 14,000 | 2,254,315 |
| President of Research and Development | ||||||||
| Nathan Dowden | 499,200 | 0 | 725,952 | 760,363 | 224,640 | 0 | 13,342 | 2,223,497 |
| President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dipal Doshi | $3,837,737 | $3,891,503 | — | −53,766 |
| Natarajan Sethuraman | 2,254,315 | 1,962,700 | — | +291,615 |
| Nathan Dowden | 2,223,497 | 2,460,688 | — | −237,191 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nathan Dowden | President & COO | 2026-05-04 | A | 15,000 | $2 | $26,100 | Common | Form 4 ↗ |
| Natarajan Sethuraman | President, Research & Develop. | 2026-05-04 | D | 25,907 | 15 | 398,810 | Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-05-04 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-05-04 | D | 15,000 | 15 | 229,953 | Common | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-05-20 | A | 5,000 | 6 | 29,316 | Common, indirect | Form 4 ↗ |
| Peter S. Kim | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gina Chapman | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Thistle | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maha Radhakrishnan | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Dipal Doshi | PSU | — | — | — | — | — | $1,387,428 |
| Nathan Dowden | Option | — | — | — | — | — | 760,363 |
| Dipal Doshi | Option | — | — | — | — | — | 1,452,059 |
| Nathan Dowden | PSU | — | — | — | — | — | 725,952 |
| Natarajan Sethuraman | PSU | — | — | — | — | — | 725,952 |
| Natarajan Sethuraman | Option | — | — | — | — | — | 760,363 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Dipal Doshi | $0 | $1,387,428 | $1,452,059 | 48.9% |
| Nathan Dowden | 0 | 725,952 | 760,363 | 48.8% |
| Natarajan Sethuraman | 0 | 725,952 | 760,363 | 48.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Natarajan Sethuraman | Option | 9,406 | 15.41 | — |
| Dipal Doshi | Option | 11,344 | 11.57 | — |
| Nathan Dowden | RSU | 24,825 | — | 255,201 |
| Natarajan Sethuraman | RSU | 7,100 | — | 72,988 |
| Nathan Dowden | RSU | 7,100 | — | 72,988 |
| Natarajan Sethuraman | Option | 4,345 | 11.57 | — |
| Natarajan Sethuraman | RSU | 80,000 | — | 822,400 |
| Nathan Dowden | RSU | 2,816 | — | 28,948 |
| Nathan Dowden | Option | 9,406 | 15.41 | — |
| Nathan Dowden | Option | 28,181 | 13.73 | — |
| Dipal Doshi | RSU | 116,200 | — | 1,194,536 |
| Dipal Doshi | RSU | 100,000 | — | 1,028,000 |
| Nathan Dowden | RSU | 30,000 | — | 308,400 |
| Dipal Doshi | RSU | 24,825 | — | 255,201 |
| Dipal Doshi | RSU | 3,781 | — | 38,869 |
| Nathan Dowden | RSU | 1,408 | — | 14,474 |
| Dipal Doshi | Option | 32,922 | 15.41 | — |
| Natarajan Sethuraman | Option | 5,070 | 12 | — |
| Dipal Doshi | RSU | 78,525 | — | 807,237 |
| Natarajan Sethuraman | RSU | 33,075 | — | 340,011 |
| Dipal Doshi | RSU | 7,562 | — | 77,737 |
| Natarajan Sethuraman | RSU | 1,448 | — | 14,885 |
| Dipal Doshi | Option | 13,234 | 12 | — |
| Nathan Dowden | Option | 6,719 | 12.25 | — |
| Natarajan Sethuraman | RSU | 2,897 | — | 29,781 |
| Natarajan Sethuraman | Option | 90,800 | 11.94 | — |
| Natarajan Sethuraman | Option | 37,575 | 13.73 | — |
| Nathan Dowden | Option | 4,223 | 11.57 | — |
| Nathan Dowden | Option | 4,927 | 12 | — |
| Nathan Dowden | Option | 90,800 | 11.94 | — |
| Dipal Doshi | Option | 23,516 | 12.25 | — |
| Dipal Doshi | Option | 89,156 | 13.73 | — |
| Dipal Doshi | Option | 173,400 | 11.94 | — |
| Nathan Dowden | RSU | 60,000 | — | 616,800 |
| Nathan Dowden | RSU | 60,800 | — | 625,024 |
| Natarajan Sethuraman | Option | 6,719 | 12.25 | — |
| Natarajan Sethuraman | RSU | 60,800 | — | 625,024 |
Compensation for named executive officers consists of a combination of base salary, cash bonuses, and long-term incentive compensation in the form of stock options, RSUs and PSUs, designed to be competitive and aligned with the company's business and executive talent requirements.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maha Radhakrishnan, M.DIndependent · Audit · Newly elected | $28,538 | $0 | $202,388 | — | $1 | $230,927 |
| Kush M. Parmar, M.D., Ph.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair) | 98,209 | 0 | 104,388 | — | 0 | 202,597 |
| Mary ThistleIndependent · Audit (Chair) · Compensation | 63,038 | 0 | 104,388 | — | 1 | 167,427 |
| Gina ChapmanIndependent · Audit · Nominating/Governance | 53,165 | 0 | 104,388 | — | — | 157,553 |
| Bernhardt Zeiher, M.DIndependent · Compensation | 46,291 | 0 | 104,388 | — | 1 | 150,680 |
| Peter S. Kim, Ph.DNot independent | 40,000 | 0 | 104,388 | — | 0 | 144,388 |
| Dipal DoshiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 9,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $329,241 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $3 |
| Total cost of the board | $329,244 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Entrada Therapeutics | 2025 | Dipal Doshi | $635,000 | $1,387,428 | $1,452,059 | $349,250 | $3,837,737 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Dipal Doshi | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “2025 Summary Compensation Table”. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |
| 2 | Section 01, Natarajan Sethuraman | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “2025 Summary Compensation Table”. As printed: 2,254,315. Filing ↗machine: t12 · r4 · c14 · span 341380–341389 |
| 3 | Section 01, Nathan Dowden | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “2025 Summary Compensation Table”. As printed: 2,223,497. Filing ↗machine: t12 · r6 · c14 · span 345914–345923 |
| 4 | Section 03, Dipal Doshi PSU | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c6 · span 335548–335557 |
| 5 | Section 03, Nathan Dowden Option | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r6 · c8 · span 344988–344995 |
| 6 | Section 03, Dipal Doshi Option | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c8 · span 335885–335894 |
| 7 | Section 03, Nathan Dowden PSU | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r6 · c6 · span 344679–344686 |
| 8 | Section 03, Natarajan Sethuraman PSU | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r4 · c6 · span 340345–340352 |
| 9 | Section 03, Natarajan Sethuraman Option | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r4 · c8 · span 340604–340611 |
| 10 | Section 07, pay ratio | 10-K | 2026-02-26 | 0001689375-26-000011 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Maha Radhakrishnan, M.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 230,927. Filing ↗ |
| 12 | Section 08, Kush M. Parmar, M.D., Ph.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 202,597. Filing ↗ |
| 13 | Section 08, Mary Thistle | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 167,427. Filing ↗machine: t16 · r3 · c7 · span 523758–523765 |
| 14 | Section 08, Gina Chapman | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 157,553. Filing ↗machine: t16 · r6 · c7 · span 528532–528539 |
| 15 | Section 08, Bernhardt Zeiher, M.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 150,680. Filing ↗ |
| 16 | Section 08, Peter S. Kim, Ph.D | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 144,388. Filing ↗ |
| 17 | Section 08, Dipal Doshi | DEF 14A | 2026-04-24 | 0001689375-26-000021 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 02, Nathan Dowden 2026-05-04 | Form 4 | 2026-05-04 | 0001873392-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Natarajan Sethuraman 2026-05-04 | Form 4 | 2026-05-04 | 0001873394-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Nathan Dowden 2026-05-04 | Form 4 | 2026-05-04 | 0001873392-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Nathan Dowden 2026-05-04 | Form 4 | 2026-05-04 | 0001873392-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Bernhardt G. Zeiher 2026-05-20 | Form 4 | 2026-05-21 | 0001689375-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Peter S. Kim 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Gina Chapman 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Mary Thistle 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Maha Radhakrishnan 2026-06-10 | Form 4 | 2026-06-12 | 0002013423-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Bernhardt G. Zeiher 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Kush Parmar 2026-06-10 | Form 4 | 2026-06-12 | 0001689375-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 30 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 31 | Section 09b board cost (computed) | Computed | — | computed | Cash 329,241 + equity 0 + all other 3 = 329,244, summed across the director compensation table rows.machine: formula: Σ = 329,244 |
| 32 | Entrada Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001689375-26-000021 | CEO total compensation as printed in Entrada Therapeutics's own proxy. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |